Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2539-2543

  Taba, Kumiko ^a   Kuramitsu, Yasuhiro ^a   Ryozawa, Shomei ^a   Yoshida, Kanako ^a   Tanaka, Toshiyuki ^a   Maehara, Shin Ichiro ^b   Maehara, Yoshihiro ^b   Sakaida, Isao ^a   Nakamura, Kazuyuki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

2 DE; GEM; Gemcitabine; Heat shock protein 27; LC MS MS; Pancreatic cancer; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

GEMCITABINE; HEAT SHOCK PROTEIN 27;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HSP27 HEAT-SHOCK PROTEINS; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN ISOFORMS; UP-REGULATION;

EID: 77955832992     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Williamson RC: Pancreatic cancer: the greatest oncological challenge. Br Med J (Clin Res Ed) 13: 445-446, 1988.
2. Gordis L and Gold EB: Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
3. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 1-5, 1996.
4. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuriya K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat-shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31: 1345-1350, 2007.
5. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, Nakamura K and Sakaida I: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1: 429-434, 2008.
6. Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Interferon-γ down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Pancreas 38: 224-226, 2009.
7. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112: 184-189, 2004. (Pubitemid 39244357)
8. Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M and Nakamura K: Down-regulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis 29: 2651-2659, 2008. (Pubitemid 351911893)
9. Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K and Nakamura K: Proteomic differential display analysis identified up-regulated astrocytic phsphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 9: 5078-5089, 2009.
10. Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, Okita K, Oka M and Nakamura K: Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 27: 1651-1658, 2006.
11. Tamesa M, Kuramitsu Y, Fujimoto M, Maeda N, Nagashima Y, Tanaka T, Yamamoto S, Oka M and Nakamura K: Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 30: 2168-2181, 2009.
12. Arrigo AP: Hsp27: novel regulator of intracellular redox state. IUBMB Life 52: 303-307, 2001.
13. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG and Fuqua SA: Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56: 187-196, 1999. (Pubitemid 29494836)
14. Gibbons NB, Watson RW, Coffey RN, Brady HP and Fitzpatrick JM: Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45: 58-65, 2000.
15. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnölzer M, Sinha P and Federici G: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5: 796-804, 2005. (Pubitemid 40316064)
16. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL and Fuqua SA: Biological and clinical implications of heat-shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 85: 1558-1570, 1993.
17. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS: Heat-shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000. (Pubitemid 32059190)
18. Romanucci M, Marinelli A, Sarli G and Della Salda L: Heat-shock protein expression in canine malignant mammary tumours. BMC Cancer 6: 171, 2006.
19. Landry J, Lambert H, Zhou M, Lavoie JN, Hickey E, Weber LA and Anderson CW: Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem 267: 794-803, 1992.
20. Döppler H, Storz P, Li J, Comb MJ and Toker A: A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J Biol Chem 280: 15013-15019, 2005. (Pubitemid 40562854)